Enterobacteriaceae
BacteriologyThe Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical IsolatesWith multidrug-resistant (MDR) Enterobacterales on the rise, a nontoxic antimicrobial agent with a unique mechanism of action such as fosfomycin seems attractive. However, establishing accurate fosfomycin susceptibility testing for non-Escherichia coli isolates in a clinical microbiology laboratory remains problematic. We evaluated fosfomycin susceptibility...
EpidemiologyGenomics for Molecular Epidemiology and Detecting Transmission of Carbapenemase-Producing Enterobacterales in Victoria, Australia, 2012 to 2016Carbapenemase-producing Enterobacterales (CPE) are being increasingly reported in Australia, and integrated clinical and genomic surveillance is critical to effectively manage this threat. We sought to systematically characterize CPE in Victoria, Australia, from 2012 to 2016.
BacteriologyDevelopment of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor EnmetazobactamThird-generation cephalosporin resistance among Enterobacteriaceae, mediated by the spread of extended-spectrum β-lactamases (ESBLs), is a very serious medical concern with limited therapeutic options. Enmetazobactam (formerly AAI101) is a novel penicillanic sulfone β-lactamase inhibitor active against a wide range of ESBLs. The combination of enmetazobactam and...
BacteriologyReduced Incubation Time of the Modified Carbapenem Inactivation Test and Performance of Carbapenem Inactivation in a Set of Carbapenemase-Producing Enterobacteriaceae with a High Proportion of blaIMP IsolatesAccurate and timely identification of carbapenemase-producing Enterobacteriaceae (CPE) is critical for microbiology laboratories in order to facilitate infection prevention, reduce the spread of multiresistant Gram-negative bacilli, and reduce delays to effective antibiotic therapy. We undertook a study to compare the carbapenem inactivation method (CIM) against the...
BacteriologyEvaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019 Enterobacteriaceae CLSI BreakpointsIn 2019, the Clinical and Laboratory Standards Institute (CLSI) published revisions to the Enterobacteriaceae ciprofloxacin and levofloxacin breakpoints. We evaluated the performance of disk diffusion and Etest compared to that of reference broth microdilution by use of the revised breakpoints.